List of Spiriva drug patents
Spiriva is owned by Boehringer Ingelheim.
Spiriva contains Tiotropium Bromide.
Spiriva has a total of 12 drug patents out of which 7 drug patents have expired.
Expired drug patents of Spiriva are:
- US7070800
- US6777423*PED
- US7642268*PED
- US7309707*PED
- US6908928*PED
- USRE38912*PED
- US7070800*PED
Spiriva was authorised for market use on 30 January, 2004.
Spiriva is available in powder;inhalation dosage forms.
Spiriva can be used as administration of an inhalable powder comprising tiotropium via device, for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema.
The generics of Spiriva are possible to be released after 19 April, 2030.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7070800 | BOEHRINGER INGELHEIM | Inhalable powder containing tiotropium |
Jan, 2022
(1 year, 4 months ago) | |
|
US6777423 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
Mar, 2022
(1 year, 2 months ago) | |
|
US7642268 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
Mar, 2022
(1 year, 2 months ago) | |
|
US7309707 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
Mar, 2022
(1 year, 2 months ago) | |
|
US6908928 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
Mar, 2022
(1 year, 2 months ago) | |
|
USRE38912 (Pediatric) | BOEHRINGER INGELHEIM | Process for preparing powder formulations |
Apr, 2022
(1 year, 1 month ago) | |
|
US7070800 (Pediatric) | BOEHRINGER INGELHEIM | Inhalable powder containing tiotropium |
Jul, 2022
(10 months ago) | |
| US8022082 | BOEHRINGER INGELHEIM | Method for the administration of an anticholinergic by inhalation |
Jan, 2026
(2 years from now) | |
|
US8022082 (Pediatric) | BOEHRINGER INGELHEIM | Method for the administration of an anticholinergic by inhalation |
Jul, 2026
(3 years from now) | |
| US7694676 | BOEHRINGER INGELHEIM | Dry powder inhaler |
Mar, 2027
(3 years from now) | |
|
US7694676 (Pediatric) | BOEHRINGER INGELHEIM | Dry powder inhaler |
Sep, 2027
(4 years from now) | |
| US9010323 | BOEHRINGER INGELHEIM | Inhaler and sieve for an inhaler |
Apr, 2030
(6 years from now) | |
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 30 January, 2004
Treatment: For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema; Administration of an inha...
Dosage: POWDER;INHALATION
SPIRIVA family patents
17
United States
11
European Union
6
Japan
5
Poland
5
Canada
5
Germany
5
Spain
5
Australia
4
ME
4
Hong Kong
4
China
4
Denmark
4
New Zealand
4
EA
4
Portugal
3
Yugoslavia
3
Peru
3
Slovenia
3
Korea, Republic of
3
Ukraine
3
Brazil
3
Taiwan
3
Croatia
3
Hungary
3
Argentina
3
Uruguay
3
Mexico
3
Norway
3
South Africa
3
Israel
3
Malaysia
2
Saudi Arabia
2
Slovakia
2
Estonia
2
Egypt
2
Bulgaria
2
Czech Republic
2
Ecuador
2
Austria
1
Georgia
1
Algeria
1
Costa Rica
1
Turkey
1
Iceland
1
Morocco
1
Cyprus
1
AP
1
OA
1
Cuba
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic